Advancing a first-in-class treatment for difficult-to-treat cancers
Edgewood Oncology is a clinical-stage biotechnology company that was founded to deliver on the promise of BTX-A51 for patients with hematologic malignancies and genetically-defined solid tumors. Our mission is to develop an innovative medicine that improves and extends the lives of patients with the greatest unmet medical needs.
The Leadership Team
Our leadership team has a proven track record of scientific expertise and commercial value creation.
David N. Cook, Ph.D.
Chief Executive Officer
Zung Thai, M.D., Ph.D.
Chief Medical Officer
Board of Directors
Scientific Founder
Yinon Ben-Neriah,
M.D., Ph.D.
Professor of Immunology and Cancer Research
Hebrew University of Jerusalem